Humanwell Healthcare (Group) Co. Ltd. has synthesized prostaglandin E2 receptor EP2 subtype (PTGER2; EP2) and EP4 antagonists reported to be useful for the treatment of cancer, inflammation, neurodegeneration, autoimmune and cardiovascular diseases.
Researchers at Bioventures LLC and Yale University have disclosed dual inhibitors of bromodomain-containing protein 4 (BRD4; HUNK1) and histone deacetylase (HDAC) reported to be useful for the treatment of cancer and psoriasis.
CLN-617 is a single-chain fusion protein comprising human IL-2, human IL-12, leukocyte-associated immunoglobulin-like receptor 2 (LAIR2) and human serum albumin (HSA). It was designed for intratumoral injection to co-deliver IL-2 and IL-12 on a single molecule, with HSA and LAIR2 being used to retain CLN-617 in the tumor by binding collagen and increasing molecular weight.
Researchers from Molecular Partners AG reported on the preclinical evaluation of MP-0533, a multispecific T-cell engaging DARPin (designed ankyrin repeat protein) targeting CD70, CD123, CD33 and CD3 tumor-associated antigens (TAA) simultaneously.
Researchers from the Johns Hopkins University School of Medicine have hypothesized that LP-184 could synergize with the PARP inhibitor rucaparib, which avoids DNA repairing in tumor cells, for the treatment of atypical teratoid rhabdoid tumor.
Scientists at the University of Washington have engineered human plasma B cells modified to express long-lasting bispecific antibodies that could be used to treat leukemia without requiring continuous dosing.
“We are trying to engineer plasma cells to make as a stable source for biologic drugs. One thing that is really unique about plasma cells is that they can live for a really long time … up to 10 years or even 100 years depending on the type of plasma cell that that you make,” Richard James, senior author of the study, principal investigator at Seattle Children’s Research Institute, and associate professor at the University of Washington, told BioWorld.
JS Innomed Holdings Ltd. has divulged transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer, neurodegeneration, renal and cardiovascular disorders.
Captor Therapeutics Inc. has disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety covalently linked to an induced myeloid leukemia cell differentiation protein MCL-1-targeting moiety through a linker.
By combining both tumor diagnosis and treatment in entities such as fluorescent probes, theranostic represents a new avenue in the development of selective, safe and low-risk resistance strategies.
RSS
